AXEVIL Capital

Altos Labs Stock Price, Valuation & IPO

Private company — Altos Labs is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.

Status source: AXEVIL investment team

$21.28 per share (AXEVIL consensus estimate)

Source: AXEVIL consensus of recent secondary transactions · as of 6 October 2026

Total raised: $3B

Data last updated: 6 October 2026

About Altos Labs

Develops partial cellular reprogramming that restores a youthful gene expression pattern to treat age-related diseases. Launched in 2022 with $3 billion in investor commitments, CEO Hal Barron from GSK, approximately 550 employees in the US and UK.

Altos Labs is an American-British biotechnology company, launched in January 2022 in Redwood City with an industry-record $3 billion in investor commitments. It focuses on cellular reprogramming: cell rejuvenation as a way to treat kidney, liver, heart, and lung diseases, which share a common cause — the aging of the cells themselves. The company is led by former GSK head of research Hal Barron and Hans Bishop, who sold Juno to Celgene for $9 billion; it has about 550 employees, and among its directors and advisors are three Nobel laureates: Jennifer Doudna, Frances Arnold, and Shinya Yamanaka. In 2025, Dorian Therapeutics was acquired, and a paper on mesenchymal drift was published in Cell. There are no announced clinical programs yet.

  • Sector: Healthcare & Biotech
  • Headquarters: Redwood City, California, USA
  • Founded: 2021

Key highlights

  1. Kidneys: disease as accelerated aging. Kunya Zhang's group from Altos showed in Nature Aging that diseased kidney cells age epigenetically faster than healthy ones. This makes kidney disease a target for reprogramming.
  2. Patients: those with a weaker drift live longer. The Belmonte Group showed in Cell in 2025, using data from over 40 tissues and 20 diseases, that strong mesenchymal drift is associated with a worse outcome. A measurable marker emerges by which the effect of therapy can be evaluated.
  3. Donor organs: a short path to people. Klausner said in 2024 that old rat kidneys were treated for 45 minutes with a cocktail of factors. Treating an organ ex vivo is the fastest path to the clinic because it does not require administering the drug to the patient.

Frequently asked questions

How can I buy Altos Labs stock before the IPO?

Not on a public exchange — Altos Labs is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.

What is the Altos Labs stock price?

A private company has no single official share price. AXEVIL's consensus estimate is $21.28 per share as of 6 October 2026.

What is Altos Labs's valuation?

AXEVIL does not have a verified valuation for Altos Labs at the moment; it appears here once a priced round is on record.

When will Altos Labs IPO?

No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.

Is Altos Labs publicly traded?

No. Altos Labs is a private company and its shares are not listed on any public exchange.

Does Altos Labs have a stock symbol?

No. Altos Labs has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.

Similar companies

Risk disclosure

Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.

Full legal disclosures · All companies